Recursion’s Phase 2 Trial Brings Hope for Cerebral Cavernous Malformation Treatment
Recursion Pharmaceuticals, Inc. (Nasdaq: RXRX) has marked a significant milestone as its Phase 2 trial for the treatment of cerebral cavernous malformation continues to successfully enroll participants. The trial will investigate the effectiveness and safety of REC-994, an integrin-linked kinase inhibitor.
Cerebral cavernous malformation is a rare disease that causes abnormal blood vessels in the brain. The condition can result in seizures, headaches, and stroke, and there are currently no approved treatments. REC-994 has demonstrated promising results in preclinical studies, showing potential as a first-in-class treatment.
This makes the success of the trial even more important, as it brings hope to those suffering from this debilitating condition and is a significant step towards making this potential treatment a reality. As the trial progresses, the medical community will eagerly await the results, hoping for a breakthrough in the treatment of cerebral cavernous malformation.
About Recursion Pharmaceuticals
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
